New Gene Therapy Adds Muscle Mass in 12 MD Patients

Twelve people with a rare muscular disease just completed a trial that could change how we treat genetic conditions.

Epicrispr Biotechnologies announced that all participants in their early trial have received EPI-321, a one-time treatment for facioscapulohumeral muscular dystrophy (FSHD). This form of muscular dystrophy typically weakens muscles in the face, shoulders, and upper arms, making simple movements like smiling or lifting objects increasingly difficult.

The treatment works differently from traditional gene therapy. Instead of changing DNA itself, EPI-321 uses epigenetics to flip a genetic switch, turning off the overactive DUX4 gene that causes muscle breakdown in FSHD patients. Think of it like muting a loud alarm without removing the alarm system.

Early results from three patients tracked for six months show something remarkable. All three gained lean muscle mass, adding between half a pound to 1.3 pounds of muscle. Some individual muscles grew 15% in volume.

That might not sound like much, but for people with FSHD, it's extraordinary. These patients typically lose muscle mass over time as their disease progresses. Gaining muscle is the opposite of what should happen.

The treatment uses a modified virus called AAV to deliver its payload, a common approach in gene therapy. Six patients received a lower dose while six received a higher dose. Both groups completed treatment without serious side effects reported so far.

Why This Inspires

This trial represents the first time anyone has tested this epigenetic approach in FSHD patients. While traditional gene therapy tries to rewrite faulty genetic code, this method works with existing DNA, potentially offering a safer path forward.

The three patients monitored longest also showed improvements in strength and functionality at three months. Biomarker data suggests the treatment is doing exactly what researchers hoped, silencing the problem gene while leaving everything else intact.

Epicrispr plans to present complete findings at the World Muscle Society Annual Congress in September. All 12 participants will reach their one-year follow-up mark next year, giving researchers crucial data about whether these gains last.

For the estimated 870,000 people worldwide living with FSHD, this trial offers something in short supply: genuine hope that muscle loss might not be inevitable.